Abstract:
Irritable Bowel Syndrome is one of the most common pathological conditions. Despite progress in its knowledge of pathogenesis, large flaws still exist in our understanding of pharmacological action. This is a review of recent progress in the field of the therapy of irritable bowel syndrome. The now compounds acting on serotonine receptor did not keep promise. New therapies are under assessment, like psychotherapy or probiotics.
